Key result
Higher anxiety sensitivity links to worse exercise breathlessness and ventilatory inefficiency in HFpEF.
Why the study?
Anxiety sensitivity may influence dyspnea reports and respiratory responses in patients with HFpEF, but its impact under exercise and pharmacological challenge conditions was unclear.
Does anxiety sensitivity affect dyspnea ratings and respiratory exercise responses in patients with HFpEF?
RCT (n=53)
Single-blind
Does anxiety sensitivity affect dyspnea ratings and respiratory exercise responses in patients with HFpEF?
Anxiety sensitivity in patients with HFpEF is associated with overreporting of dyspnea and mild hyperventilation, particularly during unusual or symptom-eliciting medical situations like a pharmacological challenge.
BACKGROUND Anxiety sensitivity, the fear of anxiety symptoms, is linked to elevated symptom reports in health and illness. Dyspnea on exertion, a dominant complaint in heart failure with preserved ejection fraction (HFpEF), could be affected by this personality characteristic. We examined whether patients with HFpEF and high anxiety sensitivity provide elevated dyspnea reports in global measures or in response to cardiopulmonary exercise testing under regular or pharmacological challenge conditions. METHOD Fifty-three patients (37 women, mean age 71.4 years) with HFpEF completed the Anxiety Sensitivity Index (ASI), Dyspnoea-12 questionnaire, and modified Medical Research Council dyspnea rating (mMRC), and pulmonary function testing. They also performed six-minute constant-load cycling at 20W and incremental cycling to exhaustion, with placebo or sublingual nitroglycerin in a single-blind, cross-over design. Ratings of perceived breathlessness and its unpleasantness, and ventilation and arterial blood gas measurements, were completed at rest, during the final minute of constant-load cycling, and immediately after incremental cycling. RESULTS ASI scores predicted Dyspnoea-12, but not mMRC scores. Across rest and exercise, PaCO2 and ventilatory efficiency was lower, and minute ventilation, dead space, and breathlessness ratings were higher, under nitroglycerin challenge. Under this condition, patients with higher ASI also reported more breathlessness across the exercise protocol, required greater E to eliminate CO2 (E/ CO2), and had lower PaCO2 at pre-exercise while waiting for the nitroglycerin to take effect. CONCLUSION Overreporting of dyspnea and mild hyperventilation need to be considered when testing patients with HFpEF that are high in anxiety sensitivity in unusual medical situations that elicit symptoms.
No takes yet. Share an insight, caveat, or question.
Ritz et al. (2026) conducted an RCT in Heart failure with preserved ejection fraction (HFpEF) (n=53). Sublingual nitroglycerin vs. Placebo was evaluated on Dyspnea ratings (Dyspnoea-12, mMRC), breathlessness, and ventilatory efficiency (VE/VCO2, PaCO2). Under sublingual nitroglycerin challenge, HFpEF patients with higher anxiety sensitivity reported more breathlessness during exercise, required greater VE/VCO2, and had lower pre-exercise PaCO2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: